|
1
|
Yap TA, Zivi A, Omlin A and de Bono JS:
The changing therapeutic landscape of castration-resistant prostate
cancer. Nat Rev Clin Oncol. 8:597–610. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hodgson MC, Bowden WA and Agoulnik IU:
Androgen receptor footprint on the way to prostate cancer
progression. World J Urol. 30:279–285. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chang KH, Ercole CE and Sharifi N:
Androgen metabolism in prostate cancer: From molecular mechanisms
to clinical consequences. Br J Cancer. 111:1249–1254. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scher HI, Buchanan G, Gerald W, Butler LM
and Tilley WD: Targeting the androgen receptor: Improving outcomes
for castration resistant prostate cancer. Endocr Relat Cancer.
11:459–476. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Godbole AM and Njar VC: New insights into
the androgen-targeted therapies and epigenetic therapies in
prostate cancer. Prostate Cancer. 2011:9187072011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim W and Ryan CJ: Androgen receptor
directed therapies in castration-resistant metastatic prostate
cancer. Curr Treat Options Oncol. 13:189–200. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Harris WP, Mostaghel EA, Nelson PS and
Montgomery B: Androgen deprivation therapy: Progress in
understanding mechanisms of resistance and optimizing androgen
depletion. Nat Clin Pract Urol. 6:76–85. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lamont KR and Tindall DJ: Minireview:
Alternative activation pathways for the androgen receptor in
prostate cancer. Mol Endocrinol. 25:897–907. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brooke GN and Bevan CL: The role of
androgen receptor mutations in prostate cancer progression. Curr
Genomics. 10:18–25. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Armstrong CM and Gao AC: Drug resistance
in castration resistant prostate cancer: Resistance mechanisms and
emerging treatment strategies. Am J Clin Exp Urol. 3:64–76.
2015.PubMed/NCBI
|
|
11
|
Antonarakis ES, Armstrong AJ, Dehm SM and
Luo J: Androgen receptor variant-driven prostate cancer: Clinical
implications and therapeutic targeting. Prostate Cancer Prostatic
Dis. 19:231–241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lokhandwala PM, Riel SL, Haley L, Lu C,
Chen Y, Silberstein J, Zhu Y, Zheng G, Lin MT, Gocke CD, et al:
Analytical validation of androgen receptor splice variant 7
detection in a clinical laboratory improvement amendments (CLIA)
laboratory setting. J Mol Diagn. 19:115–125. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Del Re M, Biasco E, Crucitta S, Derosa L,
Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, et
al: The detection of androgen receptor splice variant 7 in
plasma-derived exosomal RNA strongly predicts resistance to
hormonal therapy in metastatic prostate cancer patients. Eur Urol.
71:680–687. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dehm SM, Schmidt LJ, Heemers HV, Vessella
RL and Tindall DJ: Splicing of a novel androgen receptor exon
generates a constitutively active androgen receptor that mediates
prostate cancer therapy resistance. Cancer Res. 68:5469–5477. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu R, Dunn TA, Wei S, Isharwal S, Veltri
RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, et al:
Ligand-independent androgen receptor variants derived from splicing
of cryptic exons signify hormone-refractory prostate cancer. Cancer
Res. 69:16–22. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo Z, Yang X, Sun F, Jiang R, Linn DE,
Chen H, Chen H, Kong X, Melamed J, Tepper CG, et al: A novel
androgen receptor splice variant is up-regulated during prostate
cancer progression and promotes androgen depletion-resistant
growth. Cancer Res. 69:2305–2313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun S, Sprenger CC, Vessella RL, Haugk K,
Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, et
al: Castration resistance in human prostate cancer is conferred by
a frequently occurring androgen receptor splice variant. J Clin
Invest. 120:2715–2730. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang X, Morrissey C, Sun S, Ketchandji M,
Nelson PS, True LD, Vakar-Lopez F, Vessella RL and Plymate SR:
Androgen receptor variants occur frequently in castration resistant
prostate cancer metastases. PLoS One. 6:e279702011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dehm SM and Tindall DJ: Alternatively
spliced androgen receptor variants. Endocr Relat Cancer.
18:R183–R196. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Antonarakis ES, Lu C, Wang H, Luber B,
Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, et
al: AR-V7 and resistance to enzalutamide and abiraterone in
prostate cancer. N Engl J Med. 371:1028–1038. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sarwar M, Semenas J, Miftakhova R,
Simoulis A, Robinson B, Gjörloff Wingren A, Mongan NP, Heery DM,
Johnsson H, Abrahamsson PA, et al: Targeted suppression of AR-V7
using PIP5K1α inhibitor overcomes enzalutamide resistance in
prostate cancer cells. Oncotarget. 7:63065–63081. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Watson PA, Chen YF, Balbas MD, Wongvipat
J, Socci ND, Viale A, Kim K and Sawyers CL: Constitutively active
androgen receptor splice variants expressed in castration-resistant
prostate cancer require full-length androgen receptor. Proc Natl
Acad Sci USA. 107:pp. 16759–16765. 2010; View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cao B, Qi Y, Zhang G, Xu D, Zhan Y,
Alvarez X, Guo Z, Fu X, Plymate SR, Sartor O, et al: Androgen
receptor splice variants activating the full-length receptor in
mediating resistance to androgen-directed therapy. Oncotarget.
5:1646–1656. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu D, Zhan Y, Qi Y, Cao B, Bai S, Xu W,
Gambhir SS, Lee P, Sartor O, Flemington EK, et al: Androgen
receptor splice variants dimerize to transactivate target genes.
Cancer Res. 75:3663–3671. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y and Tang L: Discovery and
development of sulforaphane as a cancer chemopreventive
phytochemical. Acta Pharmacol Sin. 28:1343–1354. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Clarke JD, Dashwood RH and Ho E:
Multi-targeted prevention of cancer by sulforaphane. Cancer Lett.
269:291–304. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cheung KL and Kong AN: Molecular targets
of dietary phenethyl isothiocyanate and sulforaphane for cancer
chemoprevention. AAPS J. 12:87–97. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fawzy Elbarbry and Nehad Elrody: Potential
health benefits of sulforaphane: A review of the experimental,
clinical and epidemiological evidences and underlying mechanisms. J
Med Plants Res. 5:473–484. 2011.
|
|
29
|
Shapiro TAI, Fahey JW, Dinkova-Kostova AT,
Holtzclaw WD, Stephenson KK, Wade KL, Ye L and Talalay P: Safety,
tolerance, and metabolism of broccoli sprout glucosinolates and
isothiocyanates: a clinical phase I study. Nutr Cancer. 55:53–62.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Petri N, Tannergren C, Holst B, Mellon FA,
Bao Y, Plumb GW, Bacon J, O'Leary KA, Kroon PA, Knutson L, et al:
Absorption/metabolism of sulforaphane and quercetin, and regulation
of phase II enzymes, in human jejunum in vivo. Drug Metab Dispos.
31:805–813. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Keum YS, Khor TO, Lin W, Shen G, Kwon KH,
Barve A, Li W and Kong AN: Pharmacokinetics and pharmacodynamics of
broccoli sprouts on the suppression of prostate cancer in
transgenic adenocarcinoma of mouse prostate (TRAMP) mice:
Implication of induction of Nrf2, HO-1 and apoptosis and the
suppression of Akt-dependent kinase pathway. Pharm Res.
26:2324–2331. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Traka MH, Melchini A and Mithen RF:
Sulforaphane and prostate cancer interception. Drug Discov Today.
19:1488–1492. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim SH and Singh SV: D,L-Sulforaphane
causes transcriptional repression of androgen receptor in human
prostate cancer cells. Mol Cancer Ther. 8:1946–1954. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wiczk A, Hofman D, Konopa G and
Herman-Antosiewicz A: Sulforaphane, a cruciferous vegetable-derived
isothiocyanate, inhibits protein synthesis in human prostate cancer
cells. Biochim Biophys Acta. 1823:1295–1305. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Burnett JP, Lim G, Li Y, Shah RB, Lim R,
Paholak HJ, McDermott SP, Sun L, Tsume Y, Bai S, et al:
Sulforaphane enhances the anticancer activity of taxanes against
triple negative breast cancer by killing cancer stem cells. Cancer
Lett. 394:52–64. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li QQ, Xie YK, Wu Y, Li LL, Liu Y, Miao
XB, Liu QZ, Yao KT and Xiao GH: Sulforaphane inhibits cancer
stem-like cell properties and cisplatin resistance through
miR-214-mediated downregulation of c-MYC in non-small cell lung
cancer. Oncotarget. 8:12067–12080. 2017.PubMed/NCBI
|
|
37
|
Singh SV, Srivastava SK, Choi S, Lew KL,
Antosiewicz J, Xiao D, Zeng Y, Watkins SC, Johnson CS, Trump DL, et
al: Sulforaphane-induced cell death in human prostate cancer cells
is initiated by reactive oxygen species. J Biol Chem.
280:19911–19924. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xiao D, Powolny AA, Antosiewicz J, Hahm
ER, Bommareddy A, Zeng Y, Desai D, Amin S, Herman-Antosiewicz A and
Singh SV: Cellular responses to cancer chemopreventive agent
D,L-sulforaphane in human prostate cancer cells are initiated by
mitochondrial reactive oxygen species. Pharm Res. 26:1729–1738.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pei Y, Wu B, Cao Q, Wu L and Yang G:
Hydrogen sulfide mediates the anti-survival effect of sulforaphane
on human prostate cancer cells. Toxicol Appl Pharmacol.
257:420–428. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang C, Su Z-Y, Khor TO, Shu L and Kong
AN: Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP
C1 cells through epigenetic regulation. Biochem Pharmacol.
85:1398–1404. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kensler TW, Egner PA, Agyeman AS,
Visvanathan K, Groopman JD, Chen JG, Chen TY, Fahey JW and Talalay
P: Keap1-nrf2 signaling: A target for cancer prevention by
sulforaphane. Top Curr Chem. 329:163–177. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schultz MA, Hagan SS, Datta A, Zhang Y,
Freeman ML, Sikka SC, Abdel-Mageed AB and Mondal D: Nrf1 and Nrf2
transcription factors regulate androgen receptor transactivation in
prostate cancer cells. PLoS One. 9:e872042014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gibbs A, Schwartzman J, Deng V and Alumkal
J: Sulforaphane destabilizes the androgen receptor in prostate
cancer cells by inactivating histone deacetylase 6. Proc Natl Acad
Sci USA. 106:pp. 16663–16668. 2009; View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Myzak MC, Hardin K, Wang R, Dashwood RH
and Ho E: Sulforaphane inhibits histone deacetylase activity in
BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis.
27:811–819. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tortorella SM, Royce SG, Licciardi PV and
Karagiannis TC: Dietary sulforaphane in cancer chemoprevention: The
role of epigenetic regulation and HDAC inhibition. Antioxid Redox
Signal. 22:1382–1424. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Khurana N, Talwar S, Chandra PK, Sharma P,
Abdel-Mageed AB, Mondal D and Sikka SC: Sulforaphane increases the
efficacy of anti-androgens by rapidly decreasing androgen receptor
levels in prostate cancer cells. Int J Oncol. 49:1609–1619. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wu HC, Hsieh JT, Gleave ME, Brown NM,
Pathak S and Chung LW: Derivation of androgen-independent human
LNCaP prostatic cancer cell sublines: Role of bone stromal cells.
Int J Cancer. 57:406–412. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li Y, Karagöz GE, Seo YH, Zhang T, Jiang
Y, Yu Y, Duarte AM, Schwartz SJ, Boelens R, Carroll K, et al:
Sulforaphane inhibits pancreatic cancer through disrupting
Hsp90-p50(Cdc37) complex and direct interactions with amino acids
residues of Hsp90. J Nutr Biochem. 23:1617–1626. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Uygur B and Wu W-S: SLUG promotes prostate
cancer cell migration and invasion via CXCR4/CXCL12 axis. Mol
Cancer. 10:1392011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Scher HI, Fizazi K, Saad F, Taplin ME,
Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et
al: AFFIRM Investigators: Increased survival with enzalutamide in
prostate cancer after chemotherapy. N Engl J Med. 367:1187–1197.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ryan CJ and Cheng ML: Abiraterone acetate
for the treatment of prostate cancer. Expert Opin Pharmacother.
14:91–96. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz
CT, Evans CP and Gao AC: Niclosamide inhibits androgen receptor
variants expression and overcomes enzalutamide resistance in
castration-resistant prostate cancer. Clin Cancer Res. 20:3198–210.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Liu C, Armstrong C, Zhu Y, Lou W and Gao
AC: Niclosamide enhances abiraterone treatment via inhibition of
androgen receptor variants in castration resistant prostate cancer.
Oncotarget. 7:32210–32220. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Goldman JW, Raju RN, Gordon GA, El-Hariry
I, Teofilivici F, Vukovic VM, Bradley R, Karol MD, Chen Y, Guo W,
et al: A first in human, safety, pharmacokinetics, and clinical
activity phase I study of once weekly administration of the Hsp90
inhibitor ganetespib (STA-9090) in patients with solid
malignancies. BMC Cancer. 13:1522013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Thakur MK, Heilbrun LK, Sheng S, Stein M,
Liu G, Antonarakis ES, Vaishampayan U, Dzinic SH, Li X, Freeman S,
et al: A phase II trial of ganetespib, a heat shock protein 90
Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic
castrate-resistant prostate cancer (CRPC)-a prostate cancer
clinical trials consortium (PCCTC) study. Invest New Drugs.
34:112–118. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Goyal L, Wadlow RC, Blaszkowsky LS, Wolpin
BM, Abrams TA, McCleary NJ, Sheehan S, Sundaram E, Karol MD, Chen
J, et al: A phase I and pharmacokinetic study of ganetespib
(STA-9090) in advanced hepatocellular carcinoma. Invest New Drugs.
33:128–137. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hong DS, Kurzrock R, Supko JG, He X, Naing
A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, et al: A
phase I first-in-human trial of bardoxolone methyl in patients with
advanced solid tumors and lymphomas. Clin Cancer Res. 18:3396–3406.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Gao X, Deeb D, Liu Y, Arbab AS, Divine GW,
Dulchavsky SA and Gautam SC: Prevention of prostate cancer with
oleanane synthetic triterpenoid CDDO-Me in the TRAMP mouse model of
prostate cancer. Cancers (Basel). 3:3353–3369. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Alumkal JJ, Slottke R, Schwartzman J,
Cherala G, Munar M, Graff JN, Beer TM, Ryan CW, Koop DR, Gibbs A,
et al: A phase II study of sulforaphane-rich broccoli sprout
extracts in men with recurrent prostate cancer. Invest New Drugs.
33:480–489. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Shapiro TA, Fahey JW, Dinkova-Kostova AT,
Holtzclaw WD, Stephenson KK, Wade KL, Ye L and Talalay P: Safety,
tolerance, and metabolism of broccoli sprout glucosinolates and
isothiocyanates: a clinical phase I study. Nutr Cancer. 55:53–62.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Cunningham D and You Z: In vitro and in
vivo model systems used in prostate cancer research. J Biol
Methods. 2:e172015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Li Y, Hwang TH, Oseth LA, Hauge A,
Vessella RL, Schmechel SC, Hirsch B, Beckman KB, Silverstein KA and
Dehm SM: AR intragenic deletions linked to androgen receptor splice
variant expression and activity in models of prostate cancer
progression. Oncogene. 31:4759–4767. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Lilienbaum A: Relationship between the
proteasomal system and autophagy. Int J Biochem Mol Biol. 4:1–26.
2013.PubMed/NCBI
|
|
65
|
Jaworski T: Degradation and beyond:
control of androgen receptor activity by the proteasome system.
Cell Mol Biol Lett. 11:109–131. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Gan N, Wu YC, Brunet M, Garrido C, Chung
FL, Dai C and Mi L: Sulforaphane activates heat shock response and
enhances proteasome activity through up-regulation of Hsp27. J Biol
Chem. 285:35528–35536. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Miyahara K, Kazama H, Kokuba H, Komatsu S,
Hirota A, Takemura J, Hirasawa K, Moriya S, Abe A, Hiramoto M, et
al: Targeting bortezomib-induced aggresome formation using
vinorelbine enhances the cytotoxic effect along with ER stress
loading in breast cancer cell lines. Int J Oncol. 49:1848–1858.
2016.PubMed/NCBI
|
|
68
|
Guthrie CR and Kraemer BC: Proteasome
inhibition drives HDAC6-dependent recruitment of tau to aggresomes.
J Mol Neurosci. 45:32–41. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zaarur N, Meriin AB, Bejarano E, Xu X,
Gabai VL, Cuervo AM and Sherman MY: Proteasome failure promotes
positioning of lysosomes around the aggresome via local block of
microtubule-dependent transport. Mol Cell Biol. 34:1336–1348. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Moriya S, Komatsu S, Yamasaki K, Kawai Y,
Kokuba H, Hirota A, Che XF, Inazu M, Gotoh A, Hiramoto M, et al:
Targeting the integrated networks of aggresome formation,
proteasome, and autophagy potentiates ER stress-mediated cell death
in multiple myeloma cells. Int J Oncol. 46:474–486. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Azad AA, Zoubeidi A, Gleave ME and Chi KN:
Targeting heat shock proteins in metastatic castration-resistant
prostate cancer. Nat Rev Urol. 12:26–36. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
He S, Zhang C, Shafi AA, Sequeira M,
Acquaviva J, Friedland JC, Sang J, Smith DL, Weigel NL, Wada Y, et
al: Potent activity of the Hsp90 inhibitor ganetespib in prostate
cancer cells irrespective of androgen receptor status or variant
receptor expression. Int J Oncol. 42:35–43. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Shafi AA, Cox MB and Weigel NL: Androgen
receptor splice variants are resistant to inhibitors of Hsp90 and
FKBP52, which alter androgen receptor activity and expression.
Steroids. 78:548–554. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Shiota M, Yokomizo A and Naito S:
Oxidative stress and androgen receptor signaling in the development
and progression of castration-resistant prostate cancer. Free Radic
Biol Med. 51:1320–1328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Gillis JL, Selth LA, Centenera MM, Townley
SL, Sun S, Plymate SR, Tilley WD and Butler LM:
Constitutively-active androgen receptor variants function
independently of the HSP90 chaperone but do not confer resistance
to HSP90 inhibitors. Oncotarget. 4:691–704. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Wang YY, Yang YX, Zhe H, He ZX and Zhou
SF: Bardoxolone methyl (CDDO-Me) as a therapeutic agent: An update
on its pharmacokinetic and pharmacodynamic properties. Drug Des
Devel Ther. 8:2075–2088. 2014.PubMed/NCBI
|
|
77
|
Probst BL, McCauley L, Trevino I, Wigley
WC and Ferguson DA: Cancer cell growth is differentially affected
by constitutive activation of NRF2 by KEAP1 deletion and
pharmacological activation of NRF2 by the synthetic triterpenoid,
RTA 405. PLoS One. 10:e01352572015. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Huo C, Kao Y-H and Chuu C-P: Androgen
receptor inhibits epithelial-mesenchymal transition, migration, and
invasion of PC-3 prostate cancer cells. Cancer Lett. 369:103–111.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Aapro MS, Eliason JF, Krauer F and Alberto
P: Colony formation in vitro as a prognostic indicator for primary
breast cancer. J Clin Oncol. 5:890–896. 1987. View Article : Google Scholar : PubMed/NCBI
|
